FDA approves fourth batch of J&J COVID-19 vaccines
BALTIMORE, Md. – Johnson & Johnson is making progress with the production of their single-shot COVID-19 vaccine. The company is now getting more shots out of their Baltimore manufacturing facility, and into arms.
Issues with manufacturing problems at the Emergent Biosolutions facility are partly to blame for the delay. More than 60 million doses of the vaccine have been rejected over quality concerns. But on Friday, the FDA approved a fourth batch of the single-dose vaccine produced at the facility. An exact count of approved doses hasn’t been released yet, but each batch typically contains several million individual doses.
Johnson & Johnson has reported they’re trying to improve the quality of the vaccines at the Baltimore facility. In June, the FDA authorized an extension of the shelf life of the company’s COVID-19 vaccine. That authorization included increasing refrigerated storage time for the vaccine from three months to four and a half months.